Adicet Bio Inc. (ACET)
ACET trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ACET on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001720580 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $27.1M cash; operating cash flow -$20.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 9,361,596 (2026-11-03); 153,255,581 a year earlier; 43,164,522 three years earlier. 1y figure adjusted for splits (1-for-16 overall); 3y figure adjusted for splits (1-for-16 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-16 on 2025-12-30 | Source 2025-12-30 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $6.6M, sold $675K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$18.9M | -$17.9M | $27.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$21.4M | -$19.8M | $33.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$20.2M | -$21.5M | $36.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$30.5M | -$20.9M | $38.9M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$26.9M | -$22.3M | $29.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$31.2M | -$26.6M | $34.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$28.2M | -$25.4M | $28.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$28.7M | -$24.1M | $56.5M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-12 |
| Latest annual report | 10-K/A | 2026-05-20 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 683 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.9% |
| 1 month | -45.6% |
| 3 months | -66.3% |
| Year to date | -67.0% |
| 1 year | -73.8% |
| From 52-week high | -73.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier